Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept and Low Dose IL-2 in SLE
NCT05339217Phase 3Recruiting
- Start
- Feb 2023
- Primary completion
- Jul 2025
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of telitacicept, aldesleukin in systemic lupus erythematosus (SLE). Started Feb 2023; status: recruiting.
02
Drugs
telitaciceptaldesleukin
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05339217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05339217.